Spotlight on Dermatology
Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Patient with Asthma and Atopic Dermatitis and Treatment-Related Conjunctivitis
StartActivity Details
MOC Point(s)
Expires: December 20, 2021
Provided By
This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.
Target Audience
The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.
Learning Objectives
After completing this activity, the participant should be better able to:
- Recognize adverse events related to biologics used to treat atopic diseases
- Describe how to work with a multidisciplinary team to develop a treatment strategy for patients with multiple coexisting atopic diseases
Activity Description
In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world atopic dermatitis patient case that was selected from a community-based clinician submission.
Statement of Educational Need
Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients.
Faculty
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne,
Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin
Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson
& Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals,
Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer,
Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD,
UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association,
Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s
Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs
(Stock Options), Galderma, IntraDerm, Johnson & Johnson,
Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo
Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm
Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever,
Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer,
Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell,
Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin
Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson
& Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals,
Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer,
Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD,
UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties.
Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech,
GlaxoSmithKline, Novartis, Sanofi Regeneron.
Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support
is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi
Regeneron.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose.
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
There is no fee for this educational activity.
This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.
In order to receive credit for this activity, the participant must:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the activity post-test (score 75% or higher) and evaluation.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a
full-service medical education company. The winner will be selected via
automated random drawing on a quarterly basis from among all eligible entries
and notified through the contact information provided. In accordance with our
privacy policy, we do not share your information with any third parties. By
entering the sweepstakes, you grant RMEI permission to use your e-mail
address to reach you for notification and prize fulfillment. Only individuals
who complete the evaluation forms and provide contact information will be
eligible to win. Open to those who have a US postal address and who are 18
years or older. Only one prize per person and per household will be awarded.
The prize will be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information for Questions About the Activity
For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com.
Activity Details
MOC Point(s)
Expires: December 20, 2021
Provided By
This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.
Target Audience
The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.
Learning Objectives
After completing this activity, the participant should be better able to:
- Recognize adverse events related to biologics used to treat atopic diseases
- Describe how to work with a multidisciplinary team to develop a treatment strategy for patients with multiple coexisting atopic diseases
Activity Description
In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world atopic dermatitis patient case that was selected from a community-based clinician submission.
Statement of Educational Need
Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients.
Faculty
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne,
Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin
Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson
& Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals,
Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer,
Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD,
UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association,
Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s
Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs
(Stock Options), Galderma, IntraDerm, Johnson & Johnson,
Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo
Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm
Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever,
Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer,
Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell,
Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin
Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson
& Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals,
Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer,
Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD,
UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties.
Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech,
GlaxoSmithKline, Novartis, Sanofi Regeneron.
Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support
is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi
Regeneron.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose.
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
There is no fee for this educational activity.
This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.
In order to receive credit for this activity, the participant must:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the activity post-test (score 75% or higher) and evaluation.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a
full-service medical education company. The winner will be selected via
automated random drawing on a quarterly basis from among all eligible entries
and notified through the contact information provided. In accordance with our
privacy policy, we do not share your information with any third parties. By
entering the sweepstakes, you grant RMEI permission to use your e-mail
address to reach you for notification and prize fulfillment. Only individuals
who complete the evaluation forms and provide contact information will be
eligible to win. Open to those who have a US postal address and who are 18
years or older. Only one prize per person and per household will be awarded.
The prize will be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information for Questions About the Activity
For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com.
Dermatology Presentations
PILOT™ 2020 Conference Coverage - Bringing What We Learned at the Virtual EULAR Conference Into Practice
StartActivity Details
Expires: June 25, 2021
Accredited By
Target Audience
Rheumatologists, dermatologists, pulmonologists, primary care providers, and other health care providers who manage patients with ILD.
Learning Objectives
Systemic sclerosis ILD
- Describe changes over disease course
- Explain monitoring and testing
- Recognize comorbidities
- Discuss new treatment options
Chronic progressive fibrosing ILD
- Recognize diagnostic characteristics and differential diagnosis
- Explain extant medications and their limitations
- Discuss therapies on the horizon
Activity Description
Listen to experts report on current publications, posters, and sessions from a recent rheumatology conference. Faculty discuss the latest on systemic sclerosis ILD and progressive fibrosing ILD and discuss the implication of this information on current clinical practices for clinicians.
Faculty
Associate Professor of Medicine
Columbia University Irving Medical Center
New York, New York
Clinical Professor of Medicine
UCLA David Geffen School of Medicine
Los Angeles, California
Professor of Medicine
Division of Rheumatology, Department of Internal Medicine
Mayo Clinic
Rochester, Minnesota
Clinical Instructor
Department of Medicine, Division of Rheumatology
University of California, Los Angeles
Los Angeles, California
Conflict of Interest Policy/Disclosure Statement
The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.
The following faculty report that they have relevant financial relationships to disclose:
- Anca D. Askanase, MD, MPH, has served as a consultant for Abbvie and Exagen. She has also done contract research for AstraZeneca, Celgene, Eli Lilly and Company, GlaxoSmithKline, Janssen Pharmaceutica, and Pfizer.
- Robin Dore, MD, has served as a consultant for Amgen, Abbvie, Gilead, Lilly, Radius, and Sanofi. She has been on the speaker’s bureau for Amgen, Abbvie, Lilly, Pfizer, Radius, UCB, and Sanofi and has done research for Amgen, Abbvie, Biogen, Gilead, Lilly, and Pfizer.
- Eric L. Matteson, MD, has served as a consultant for Arena Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc., Gilead Sciences, and Tympobio.
- Elizabeth Volkmann, MD, MS, has served as a consultant for Boehringer Ingelheim Pharmaceuticals, Inc., and Forbius.
Accreditation Statement
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Physicians
The France Foundation designates this enduring activity for a maximum of
0.5 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC)
may utilize activities that are certified by ACCME-accredited providers
toward their requirement for certification renewal by the ANCC. A certificate
of attendance will be provided by The France Foundation, an ACCME accredited
provider.
Method of Participation/How to Receive Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity.
- Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
-
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download
Statement of Commercial Support
This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.
Contact Information for Questions About the Activity
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Activity Details
Expires: June 25, 2021
Accredited By
Target Audience
Rheumatologists, dermatologists, pulmonologists, primary care providers, and other health care providers who manage patients with ILD.
Learning Objectives
Systemic sclerosis ILD
- Describe changes over disease course
- Explain monitoring and testing
- Recognize comorbidities
- Discuss new treatment options
Chronic progressive fibrosing ILD
- Recognize diagnostic characteristics and differential diagnosis
- Explain extant medications and their limitations
- Discuss therapies on the horizon
Activity Description
Listen to experts report on current publications, posters, and sessions from a recent rheumatology conference. Faculty discuss the latest on systemic sclerosis ILD and progressive fibrosing ILD and discuss the implication of this information on current clinical practices for clinicians.
Faculty
Associate Professor of Medicine
Columbia University Irving Medical Center
New York, New York
Clinical Professor of Medicine
UCLA David Geffen School of Medicine
Los Angeles, California
Professor of Medicine
Division of Rheumatology, Department of Internal Medicine
Mayo Clinic
Rochester, Minnesota
Clinical Instructor
Department of Medicine, Division of Rheumatology
University of California, Los Angeles
Los Angeles, California
Conflict of Interest Policy/Disclosure Statement
The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.
The following faculty report that they have relevant financial relationships to disclose:
- Anca D. Askanase, MD, MPH, has served as a consultant for Abbvie and Exagen. She has also done contract research for AstraZeneca, Celgene, Eli Lilly and Company, GlaxoSmithKline, Janssen Pharmaceutica, and Pfizer.
- Robin Dore, MD, has served as a consultant for Amgen, Abbvie, Gilead, Lilly, Radius, and Sanofi. She has been on the speaker’s bureau for Amgen, Abbvie, Lilly, Pfizer, Radius, UCB, and Sanofi and has done research for Amgen, Abbvie, Biogen, Gilead, Lilly, and Pfizer.
- Eric L. Matteson, MD, has served as a consultant for Arena Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc., Gilead Sciences, and Tympobio.
- Elizabeth Volkmann, MD, MS, has served as a consultant for Boehringer Ingelheim Pharmaceuticals, Inc., and Forbius.
Accreditation Statement
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Physicians
The France Foundation designates this enduring activity for a maximum of
0.5 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC)
may utilize activities that are certified by ACCME-accredited providers
toward their requirement for certification renewal by the ANCC. A certificate
of attendance will be provided by The France Foundation, an ACCME accredited
provider.
Method of Participation/How to Receive Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity.
- Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
-
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download
Statement of Commercial Support
This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.
Contact Information for Questions About the Activity
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.